These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 34106450)
21. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706 [TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt. Abdelhamid M; Elsisi GH; Seyam A; Shafie A; Kirollos M; Emad S; Mansy S; Sobhy M J Med Econ; 2022; 25(1):450-456. PubMed ID: 35291896 [TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. McEwan P; Morgan AR; Boyce R; Bergenheim K; Gause-Nilsson IAM; Bhatt DL; Leiter LA; Johansson PA; Mosenzon O; Cahn A; Wilding JPH Diabetes Obes Metab; 2021 Apr; 23(4):1020-1029. PubMed ID: 33368855 [TBL] [Abstract][Full Text] [Related]
26. Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective. Bagepally BS; Chaikledkaew U; Youngkong S; Anothaisintawee T; Thavorncharoensap M; Dejthevaporn C; Thakkinstian A Clinicoecon Outcomes Res; 2021; 13():897-907. PubMed ID: 34712053 [TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand. Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J J Geriatr Cardiol; 2022 Nov; 19(11):822-832. PubMed ID: 36561052 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742 [TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines. Mendoza VL; Tumanan-Mendoza BA; Punzalan FER ESC Heart Fail; 2021 Dec; 8(6):5132-5141. PubMed ID: 34494399 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective. Permsuwan U; Thavorn K; Dilokthornsakul P; Saokaew S; Chaiyakunapruk N J Med Econ; 2017 Sep; 20(9):991-999. PubMed ID: 28649943 [TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China. Tang Y; Sang H Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229 [No Abstract] [Full Text] [Related]
32. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458 [TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Abegaz TM; Diaby V; Sherbeny F; Ali AA Clin Drug Investig; 2022 Jun; 42(6):501-511. PubMed ID: 35614298 [TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand. Permsuwan U; Phrommintikul A; Silavanich V Clinicoecon Outcomes Res; 2020; 12():579-588. PubMed ID: 33116697 [TBL] [Abstract][Full Text] [Related]
36. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand. Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962 [TBL] [Abstract][Full Text] [Related]
37. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction. Tang Y; Sang H ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665 [TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study. Lu H; Shang P; Zhou D Front Pharmacol; 2023; 14():1155210. PubMed ID: 37771722 [No Abstract] [Full Text] [Related]
39. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Permsuwan U; Thongprasert S; Sirichanchuen B Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Bennett H; Tank A; Evans M; Bergenheim K; McEwan P Diabetes Obes Metab; 2020 Jul; 22(7):1047-1055. PubMed ID: 32037675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]